SEMAGLUTIDE

Brand name:

• Ozempic®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Type 2 diabetes mellitus (T2DM)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New listing (Major)

Comment:

Medicine was reconsidered at the March 2020 PBAC https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/agenda/March-2020-PBAC-Meeting

Submission sponsor:

Novo Nordisk Pharmaceuticals Pty Ltd

Other PBAC consideration:

• SEMAGLUTIDE

Submission received for:

November 2019 PBAC meeting

Opportunity for consumer comment:

Open 28/08/2019 and close 09/10/2019 (see PBS Website)

PBAC meeting:

Held on 06/11/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

09/12/2019

Lodgement of required documentation:

20/12/2019

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---